Skip to main content

KZR

Stock
Health Care
Biotechnology

Performance overview

KZR Price
Price Chart

Forward-looking statistics

Beta
1.02
Risk
65.58%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.

Company info

SectorHealth Care
IndustryBiotechnology
Employees69
Market cap$49.8M

Fundamentals

Enterprise value-$66.8M
Revenue$0.0
Revenue per employee—
Profit margin0.00%
Debt to equity13.69

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$10.78
Dividend per share—
Revenue per share$0.00
Avg trading volume (30 day)$155K
Avg trading volume (10 day)$231K
Put-call ratio—

Macro factor sensitivity

Growth-8.0
Credit+9.6
Liquidity+5.5
Inflation-10.5
Commodities-7.2
Interest Rates-3.4

Valuation

Dividend yield0.00%
PEG Ratio-0.44
Price to sales—
P/E Ratio-0.44
Enterprise Value to Revenue—
Price to book0.32

Upcoming events

Next earnings dayMay 14, 2025
Next dividend day—
Ex. dividend day—

News

Top 2 Real Estate Stocks Which Could Rescue Your Portfolio In July

The most oversold stocks in the real estate sector presents an opportunity to buy into undervalued companies.

Benzinga (July 3, 2025)
Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?

Kezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research (May 27, 2025)
Top 5 Health Care Stocks That Could Blast Off This Month - Allakos (NASDAQ:ALLK), BioLife Solns (NASDAQ:BLFS)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga (August 21, 2023)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free